2026 Q2 - rapport
85 dager siden
Ordredybde
Antall
Kjøp
-
Selg
Antall
-
Siste handler
| Tid | Pris | Antall |
|---|---|---|
| 1 800 | ||
| 79 | ||
| 88 | ||
| 13 033 | ||
| 21 871 |
Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.
Fond og ETF-er med aksjen
Ingen fond rapporterer aksjen blant sine ti største beholdninger.
Kunder besøkte også
Selskapshendelser
Data hentes fra Quartr| Kommende | |
|---|---|
2026 Q3 - rapport 12. nov. | 6 dager |
| Historisk | ||
|---|---|---|
2026 Q2 - rapport 13. aug. | ||
2026 Q1 - rapport 13. mai | ||
2025 Q4 - rapport 12. feb. | ||
2025 Q3 - rapport 13. nov. 2025 | ||
2025 Q2 - rapport 14. aug. 2025 |
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Forum
Bli med i samtalen på Nordnet Social
for 20 t sidenAI generert analyse som ikke nødvendigvis representerer mine vurderinger. What the Portsmouth Delay Tells Us About Future Pace The delay in moving from a successful pilot to a commercial subscription contract at Portsmouth reveals three major structural hurdles in the NHS that Induct is currently trying to solve: 1. Validation of Clinical Data ≠ Commercial Readiness: A pilot with AstraZeneca can easily prove that the software helps patients or saves clinicians time (clinical validation). However, it does not solve the commercial validation. The NHS requires intense scrutiny over data governance (IG), compliance with DTAC (Digital Technology Assessment Criteria), liability insurance, and long-term funding sustainability before a hospital can legally sign a commercial subscription. 2. The "Pilotitis" Epidemic: The NHS is famous for running pilots funded by third parties (like pharma companies) that struggle to transition into core hospital budgets once the pilot funding ends. Induct is currently fighting to transition from an "innovation project" into a permanent "line-item expense" for Portsmouth. 3. The First Contract is Always the Hardest: Because Induct historically used an advertising-funded model, they are building a brand-new subscription framework from scratch. Portsmouth is essentially acting as the guinea pig for this legal contract. The Pace Going Forward: For any completely new hospital networks where Induct has no footprint, the pace will remain slow (12 to 18 months per contract) if they start from scratch. However, if Induct successfully finalizes the Portsmouth contract, the pace for their existing pipeline (like Hull) should speed up significantly because they can reuse the exact same legal and data compliance blueprint. When Will We See Mass Deployment? Realistically, mass deployment of Induct's platform will not happen before late 2027 or early 2028. The rollout is expected to follow a specific three-phase timeline based on the current NHS and RTP program constraints: Phase 1: Present - Mid 2027] --> [Phase 2: Mid 2027 - Late 2027] --> [Phase 3: 2028+] Portsmouth & Pipeline Blueprint RTP Spending Spike Adoption True Mass Deployment • Phase 1: The Blueprint Phase (Present to Mid-2027) • What to expect: Induct must first close the Portsmouth subscription and use that exact framework to sign 1 or 2 pipeline networks (like Hull) that they are already in discussions with. • Phase 2: The RTP Spending Spike (Mid-2027 to December 2027) • What to expect: This is when the RTP program faces its "use it or lose it" budget deadline. If AstraZeneca successfully positions Induct’s severe asthma pathway as a pre-validated, "ready-to-plug-in" solution, regional Integrated Care Boards (ICBs) looking to rapidly spend their remaining RTP allocations will buy into Induct's pre-negotiated contract framework. This will look like a cluster of 5 to 10 regional networks adopting the platform within a short window. • Phase 3: True Mass Deployment (2028 and Beyond) • What to expect: True mass deployment across dozens of NHS trusts will only happen once the platform is adopted at the ICB (Integrated Care Board) level, rather than hospital by hospital. Once an ICB buys a license, the software is deployed across an entire region simultaneously. The Shareholder Takeaway The slow pace at Portsmouth is not necessarily a sign of failure, but a sign of the grueling administrative reality of the NHS. The true test of Induct's management is whether they can finalize the Portsmouth deal before the Spring 2027 RTP funding window opens. If they miss that window, they risk missing the wave of accelerated cash deployment before the RTP program ends in December 2027.
·for 3 døgn siden-98.68% totalt Jeg selger ut og tar min tap, all tillit til dette selskapet er borte Pass på der ute med fallende kniver spesielt denne her
26. okt.Hvordan har dere det?
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Nordnet Social og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Relaterte produkter
Meglerstatistikk
Fant ingen data
2026 Q2 - rapport
85 dager siden
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Forum
Bli med i samtalen på Nordnet Social
- for 20 t sidenAI generert analyse som ikke nødvendigvis representerer mine vurderinger. What the Portsmouth Delay Tells Us About Future Pace The delay in moving from a successful pilot to a commercial subscription contract at Portsmouth reveals three major structural hurdles in the NHS that Induct is currently trying to solve: 1. Validation of Clinical Data ≠ Commercial Readiness: A pilot with AstraZeneca can easily prove that the software helps patients or saves clinicians time (clinical validation). However, it does not solve the commercial validation. The NHS requires intense scrutiny over data governance (IG), compliance with DTAC (Digital Technology Assessment Criteria), liability insurance, and long-term funding sustainability before a hospital can legally sign a commercial subscription. 2. The "Pilotitis" Epidemic: The NHS is famous for running pilots funded by third parties (like pharma companies) that struggle to transition into core hospital budgets once the pilot funding ends. Induct is currently fighting to transition from an "innovation project" into a permanent "line-item expense" for Portsmouth. 3. The First Contract is Always the Hardest: Because Induct historically used an advertising-funded model, they are building a brand-new subscription framework from scratch. Portsmouth is essentially acting as the guinea pig for this legal contract. The Pace Going Forward: For any completely new hospital networks where Induct has no footprint, the pace will remain slow (12 to 18 months per contract) if they start from scratch. However, if Induct successfully finalizes the Portsmouth contract, the pace for their existing pipeline (like Hull) should speed up significantly because they can reuse the exact same legal and data compliance blueprint. When Will We See Mass Deployment? Realistically, mass deployment of Induct's platform will not happen before late 2027 or early 2028. The rollout is expected to follow a specific three-phase timeline based on the current NHS and RTP program constraints: Phase 1: Present - Mid 2027] --> [Phase 2: Mid 2027 - Late 2027] --> [Phase 3: 2028+] Portsmouth & Pipeline Blueprint RTP Spending Spike Adoption True Mass Deployment • Phase 1: The Blueprint Phase (Present to Mid-2027) • What to expect: Induct must first close the Portsmouth subscription and use that exact framework to sign 1 or 2 pipeline networks (like Hull) that they are already in discussions with. • Phase 2: The RTP Spending Spike (Mid-2027 to December 2027) • What to expect: This is when the RTP program faces its "use it or lose it" budget deadline. If AstraZeneca successfully positions Induct’s severe asthma pathway as a pre-validated, "ready-to-plug-in" solution, regional Integrated Care Boards (ICBs) looking to rapidly spend their remaining RTP allocations will buy into Induct's pre-negotiated contract framework. This will look like a cluster of 5 to 10 regional networks adopting the platform within a short window. • Phase 3: True Mass Deployment (2028 and Beyond) • What to expect: True mass deployment across dozens of NHS trusts will only happen once the platform is adopted at the ICB (Integrated Care Board) level, rather than hospital by hospital. Once an ICB buys a license, the software is deployed across an entire region simultaneously. The Shareholder Takeaway The slow pace at Portsmouth is not necessarily a sign of failure, but a sign of the grueling administrative reality of the NHS. The true test of Induct's management is whether they can finalize the Portsmouth deal before the Spring 2027 RTP funding window opens. If they miss that window, they risk missing the wave of accelerated cash deployment before the RTP program ends in December 2027.
- ·for 3 døgn siden-98.68% totalt Jeg selger ut og tar min tap, all tillit til dette selskapet er borte Pass på der ute med fallende kniver spesielt denne her
- 26. okt.Hvordan har dere det?
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Nordnet Social og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Antall
Kjøp
-
Selg
Antall
-
Siste handler
| Tid | Pris | Antall |
|---|---|---|
| 1 800 | ||
| 79 | ||
| 88 | ||
| 13 033 | ||
| 21 871 |
Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.
Fond og ETF-er med aksjen
Ingen fond rapporterer aksjen blant sine ti største beholdninger.
Kunder besøkte også
Selskapshendelser
Data hentes fra Quartr| Kommende | |
|---|---|
2026 Q3 - rapport 12. nov. | 6 dager |
| Historisk | ||
|---|---|---|
2026 Q2 - rapport 13. aug. | ||
2026 Q1 - rapport 13. mai | ||
2025 Q4 - rapport 12. feb. | ||
2025 Q3 - rapport 13. nov. 2025 | ||
2025 Q2 - rapport 14. aug. 2025 |
Relaterte produkter
Meglerstatistikk
Fant ingen data
2026 Q2 - rapport
85 dager siden
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
Data hentes fra Quartr| Kommende | |
|---|---|
2026 Q3 - rapport 12. nov. | 6 dager |
| Historisk | ||
|---|---|---|
2026 Q2 - rapport 13. aug. | ||
2026 Q1 - rapport 13. mai | ||
2025 Q4 - rapport 12. feb. | ||
2025 Q3 - rapport 13. nov. 2025 | ||
2025 Q2 - rapport 14. aug. 2025 |
Relaterte produkter
Forum
Bli med i samtalen på Nordnet Social
- for 20 t sidenAI generert analyse som ikke nødvendigvis representerer mine vurderinger. What the Portsmouth Delay Tells Us About Future Pace The delay in moving from a successful pilot to a commercial subscription contract at Portsmouth reveals three major structural hurdles in the NHS that Induct is currently trying to solve: 1. Validation of Clinical Data ≠ Commercial Readiness: A pilot with AstraZeneca can easily prove that the software helps patients or saves clinicians time (clinical validation). However, it does not solve the commercial validation. The NHS requires intense scrutiny over data governance (IG), compliance with DTAC (Digital Technology Assessment Criteria), liability insurance, and long-term funding sustainability before a hospital can legally sign a commercial subscription. 2. The "Pilotitis" Epidemic: The NHS is famous for running pilots funded by third parties (like pharma companies) that struggle to transition into core hospital budgets once the pilot funding ends. Induct is currently fighting to transition from an "innovation project" into a permanent "line-item expense" for Portsmouth. 3. The First Contract is Always the Hardest: Because Induct historically used an advertising-funded model, they are building a brand-new subscription framework from scratch. Portsmouth is essentially acting as the guinea pig for this legal contract. The Pace Going Forward: For any completely new hospital networks where Induct has no footprint, the pace will remain slow (12 to 18 months per contract) if they start from scratch. However, if Induct successfully finalizes the Portsmouth contract, the pace for their existing pipeline (like Hull) should speed up significantly because they can reuse the exact same legal and data compliance blueprint. When Will We See Mass Deployment? Realistically, mass deployment of Induct's platform will not happen before late 2027 or early 2028. The rollout is expected to follow a specific three-phase timeline based on the current NHS and RTP program constraints: Phase 1: Present - Mid 2027] --> [Phase 2: Mid 2027 - Late 2027] --> [Phase 3: 2028+] Portsmouth & Pipeline Blueprint RTP Spending Spike Adoption True Mass Deployment • Phase 1: The Blueprint Phase (Present to Mid-2027) • What to expect: Induct must first close the Portsmouth subscription and use that exact framework to sign 1 or 2 pipeline networks (like Hull) that they are already in discussions with. • Phase 2: The RTP Spending Spike (Mid-2027 to December 2027) • What to expect: This is when the RTP program faces its "use it or lose it" budget deadline. If AstraZeneca successfully positions Induct’s severe asthma pathway as a pre-validated, "ready-to-plug-in" solution, regional Integrated Care Boards (ICBs) looking to rapidly spend their remaining RTP allocations will buy into Induct's pre-negotiated contract framework. This will look like a cluster of 5 to 10 regional networks adopting the platform within a short window. • Phase 3: True Mass Deployment (2028 and Beyond) • What to expect: True mass deployment across dozens of NHS trusts will only happen once the platform is adopted at the ICB (Integrated Care Board) level, rather than hospital by hospital. Once an ICB buys a license, the software is deployed across an entire region simultaneously. The Shareholder Takeaway The slow pace at Portsmouth is not necessarily a sign of failure, but a sign of the grueling administrative reality of the NHS. The true test of Induct's management is whether they can finalize the Portsmouth deal before the Spring 2027 RTP funding window opens. If they miss that window, they risk missing the wave of accelerated cash deployment before the RTP program ends in December 2027.
- ·for 3 døgn siden-98.68% totalt Jeg selger ut og tar min tap, all tillit til dette selskapet er borte Pass på der ute med fallende kniver spesielt denne her
- 26. okt.Hvordan har dere det?
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Nordnet Social og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Antall
Kjøp
-
Selg
Antall
-
Siste handler
| Tid | Pris | Antall |
|---|---|---|
| 1 800 | ||
| 79 | ||
| 88 | ||
| 13 033 | ||
| 21 871 |
Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.
Fond og ETF-er med aksjen
Ingen fond rapporterer aksjen blant sine ti største beholdninger.
Kunder besøkte også
Meglerstatistikk
Fant ingen data